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Although a vaccine and effective chemotherapy
against tuberculosis (TB) have been available for
more than half a century, TB was declared by the
World Health Organization (WHO) a global emer-
gency in 1993 (1, 2). The data of the WHO show that
in 2004 the number of infected persons in the global
population was almost 9 millions and about 1,7 mil-
lion people died of TB that year. Both the highest
number of deaths and the highest mortality per capi-
ta are in the WHO Africa region, where HIV has led
to rapid growth of TB epidemic, and increased the
likelihood of dying from TB. It accounts for about
13% of AIDS deaths worldwide (3).
The recommended modern therapy for TB con-
sists of two phases. First-line antituberculous med-
ications embrace: isoniazid, rifampin, pyrazinamide
and either ethambutol or streptomycin given for
approximately two months. Due to resistance, sever-
al variations in this strategy have been introduced
and sometimes more toxic alternative drugs includ-
ing ethionamide, aminosalycylic acid and ofloxacin
are used. The continuation phase lasts for about
three months and includes rifampin and isoniazid
therapy (4).
Reasons behind the failure to reduce the num-
ber of TB cases globally has been attributed to both
serious side effects (hepatitis, gastrointestinal intol-
erance, renal failure, dermatological, hematological
and neurological reactions (5-7) of currently avail-
able antituberculous drugs and widespread trends in
resistance to these drugs (8). 
In 1997, the World Health Organization and
the International Union Against Tuberculosis and
Lung Disease found resistance to the first-line drugs
in every country under investigation (9). Multidrug
resistant TB (MDR-TB) is defined as the resistance
to at least isoniazid and rifampin with or without
resistance to other drugs. Nearly three per cent of all
newly diagnosed patients have MDR-TB globally. 
Throughout the world there is an ongoing campaign
aimed at searching for new potentially antimycobac-
terial compounds that will help stop the progression
of the disease. Already several lead compounds as
well as available drugsí derivatives have been
found. Potentially antituberculous active com-
pounds include analogues of thiolactomycin (10),
1,2-diamine analogues of ethambutol (11, 12),
cyclic secondary amine substituted phenyl and ben-
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zyl nitrofuranyl amides (13) and 1-(4-fluorophenyl)-
3-(4-(1-((pyridine-4-carbonyl)-hydrazono)ethyl)-
phenyl)thiourea (14).
Recently great attention is also paid to the
antimycobacterial activity of some naturally occur-
ring (15-17) and synthetic xanthone derivatives (18-
20). Thus, herein are reported the results of study
aimed at evaluating the potential antimycobacterial
activity of several xanthone derivatives. The most
promising results of the in vitro evaluation of antitu-
berculosis activity were previously reported as a
short communication (21). Furthermore, some of the
aminoalkanolic derivatives of presented herein com-
pounds were also formerly reported for their circu-
latory and/ or anticonvulsant activity (22-24).
EXPERIMENTAL
Chemical methods and materials
Melting points were determined using a B¸chi
SMP-20 apparatus. Microanalyses were performed
on an Elementar Vario EL III (Elementar Analysen-
systeme, Hanau, Germany) in the Department of
Pharmaceutical Chemistry, Medical College, the
Jagiellonian University. All the results were within
an acceptable range. Theoretical values of logP
combined (partition coefficient) were estimated with
the Pallas 3.1.1.2. program. The IR spectra (νmax in
cm-1) were recorded on a Perkin Elmer spectrometer,
the samples were prepared as KBr pellets. The 1H
NMR spectra were performed with a Varian-
Mercury spectrometer at 300 MHz, using signal
from TMS in CDCl3 as an internal standard or on a
Bruker AMX spectrometer at 500.13 MHz and
125.17 MHz, using a signal from DMSO in DMSO-
d6 and TMS in CDCl3 as internal standard. The
results are presented in the following format: chem-
ical shift d (ppm), multiplicity, number of protons, J
values in Hertz (Hz), protonís position.
Multiplicities are showed as the abbreviations: s
(singlet), brs (broad singlet), bb (broad bond), d
(doublet), dd (doublet of doublets), ddd (double
doublet of doublets), t (triplet), dt (doublet of
triplets), q (quartet), m (multiplet). TLC was per-
formed on silica gel Kieselgel 60 F254 precoated
plates (Merck), with an appropriate developing sys-
Figure 1. Synthesis of the tested compounds [I-XX].
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Table 1. Chemical structures, log Pcomb. and some antimycobacterial data of the tested compounds [I-XX]. 
Compd. R1
R2 LogPcomb.Ü MICá Inhibitionß
Pallas (mg/mL) (%)
I
◊ 2 HCl
H 4.42 < .25 98
II
◊ 2 HCl
H 3.32 > .25 65
III
◊ 2 HCl
H 4.55 < 2.5 98
IV H 4.82 > .25 11
V H 2.79 > .25 0
VI OCH3 2.62 > .25 0
VII H 2.24 > .25 0
VIII Cl 2.72 > .25 4
IX
◊ 2 HCl
H 2.47 > 2.5 9
X
◊ HCl
H 3.20 > 2.5 35
XI
◊ HCl
H 3.58 > 2.5 32
XII
◊ HCl
H 1.47 > 2.5 35
XIII
◊ HCl
H 2.59 > 2.5 34
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tem of ethanol/ethyl acetate (1:1, v/v), chloroform
/methanol (1:2, v/v), toluene/acetone (5:3, v/v) or
toluene. Spots were visualized in UV light. Reagents
and solvents were commercially available materials
of reagent grade.
Preparation of starting materials
2-(2-Bromoethoxy)-9H-xanthen-9-one was ob-
tained from 2-hydroxy-9H-xanthen-9-one (m.p.
231OC) (25) (m.p. 236-238OC) (24). First step of this
procedure was the reaction between the parent com-
pound with redistilled 2-chloroethanol in the presence
of anhydrous potassium carbonate in acetone. The
mixture was refluxed for 48 h and hot-filtered. The
solvent was then evaporated and to the residue was
added water and 5% sodium hydroxide solution. The
mixture was stirred, then unsoluble precipitate was
filtered off and washed with water. The resulting
solid was crystallized from ethanol. The next step was
bromination with phosphorus tribromide in chloro-
form according to well-known procedures (26). 
2-(2-Hydroxyethoxy)-9H-xanthen-9-one
M.p. 151-153oC; Analysis: calcd. for C15H12O4
m.w. 256.25: %C 70.30; %H 4.72. Found: %C
69.97; %H 5.02; IR (KBr, cm-1): 3430, 2947, 1616,
1488, 1271, 1250, 1232, 1150; 1H NMR 500.13
MHz (δH ppm): 3.78 (dt, J = 4.4, J = 5.4, 2H, CH2-
OH), 4.12 (t, J = 4.4, 2H, Ar-O-CH2), 4.94 (t, J =
5.4, 1H, OH), 7.47 (ddd, J = 1.1 Hz, J = 7.1 Hz, J =
8.0 Hz, 1H, H-7), 7.48 (dd, J = 3.1 Hz, J = 9.1 Hz,
1H, H-3), 7.55 (dd, J = 0.5 Hz, J = 3.1 Hz, 1H, H-
1), 7.62 (dd, J = 0.5 Hz, J = 9.1 Hz, 1H, H-4) 7.64
(ddd, J = 0.5 Hz, J = 1.1 Hz, J = 8.5 Hz, 1H, H-5),
7.86 (ddd, J = 1.8 Hz, J = 7.1 Hz, J = 8.9 Hz, 1H, H-
6), 8.19 (ddd, J = 0.5 Hz, J = 1.8 Hz, J = 8.0 Hz, 1H,
H-8); RF = 0.53 (toluene/acetone (5:3, v/v)).
2-(2-Bromoethoxy)-9H-xanthen-9-one
M.p. 183-185oC; Analysis: calcd. for
C15H11O3Br m.w. 319.14: %C 56.40; %H 3.47.
Found: %C 56.69; %H 3.43; IR (KBr, cm-1): 1646,
1616, 1459, 1317, 1265, 1213, 1145; 1H NMR
Table 1 cont.
Compd. R1 R2 LogPcomb.Ü MICá Inhibitionß
Pallas (mg/mL) (%)
XIV
◊ HCl
H 1.60 > 2.5 63
XV H 1.57 > 2.5 3
XVI
◊ 2 HCl
H 2.08 > 2.5 25
XVII
◊ 2 HCl
H 1.37 > 2.5 14
XVIII H 2.21 < 2.5 94
XIX H 4.16 > 2.5 24
XX
◊ 2 HCl
H 3.24 > 2.5 59  
ÜPallas 3.1.1.2 [available online www.compudrug.com]. The predictions of logPcomb. values for compounds: 1-3, 9-16 and 19-20 were
determined for appropriate bases. 
áMinimal inhibitory concentration against Mycobacterium tuberculosis H37Rv.
ßMIC Rifampin = 0.25 µg mlL1 (98 % inhibition) vs. M.tuberculosis 
Synthesis and antimycobacterial assay of some xanthone derivatives 25
500.13 MHz (δH ppm): 3.84 (t, J = 5.4, 2H, CH2-Br),
4.48 (t, J = 5.4, 2H, Ar-O-CH2), 7.48 (ddd, J = 1.1
Hz, J = 7.1 Hz, J = 8.0 Hz, 1H, H-7), 7.53 (dd, J =
3.2 Hz, J = 9.1 Hz, 1H, H-3), 7.62 (dd, J = 0.5 Hz, J
= 3.2 Hz, 1H, H-1), 7.65 (dd, J = 0.5 Hz, J = 9.1 Hz,
1H, H-4) 7.65 (ddd, J = 0.5 Hz, J = 1.1 Hz, J = 8.5
Hz, 1H, H-5), 7.87 (ddd, J = 1.7 Hz, J = 7.1 Hz, J =
8.9 Hz, 1H, H-6), 8.22 (ddd, J = 0.5 Hz, J = 1.7 Hz,
J = 8.0 Hz, 1H, H-8); RF = 0.86 (toluene/acetone
(5:3, v/v)).
General procedure for the synthesis of I-VI
and IX (see scheme in Figure 1): To a mixture of 2-
(2-bromoethoxy)-9H-xanthen-9-one (for I) (3.19 g,
10 mmol) or 2-(bromomethyl)-9H-xanthen-9-one
(for II-V and IX) (2.89 g, 10 mmol) or 2-(bro-
momethyl)-6-methoxy-9H-xanthen-9-one (for VI)
(3.20 g, 10 mmol) and anhydrous potassium carbon-
ate (1.38 g, 10 mmol) in toluene (40 mL) the appro-
priate amine (12 mmol) was added. The mixture was
refluxed for 4-5 h and then the solvent was evapo-
rated. The residue was dissolved in the appropriate
amount of hot 2% HCl and purified with charcoal.
From the cooled filtrate the precipitate was separat-
ed by addition of 10% NaOH. The separated solid
was dried and recrystallized from toluene. Four
bases were converted into hydrochloride salts (I-III
and IX) in propanol/acetone (4:1, v/v) with an
excess of ethanol saturated with HCl. 
Synthesis and properties of the parent com-
pounds of II-VI were previously reported (23, 27).
The appropriate phenoxyethyl piperazines necessary
to obtained of I-IV were synthesized according to
the procedure described formerly in literature (26). 
Synthesis of VII-VIII was carried out by N-acyla-
tion of ethyl 1-piperazinecarboxylate with 9-oxo-
9H-xanthene-2-carbonyl chloride (for VII) or 6-
chloro-9-oxo-9H-xanthene-2-carbonyl chloride (for
VIII) (28) in toluene in the presence of K2CO3
according to the well known procedure. 
Compounds X-XX were prepared earlier by
amination of 2-(2,3-epoxypropoxy-9H-xanthen-9-
one) with appropriate amines in n-propanol accord-
ing to the earlier published procedures (24). 
Physicochemical data of the tested compounds 
2-(2-(4-(2-(4-Chloro-3-methylphenoxy)ethyl)piper-
azin-1-yl)ethoxy)-9H-xanthen-9-one dihydrochlo-
ride (I)
M.p. 249-251OC; Analysis: calcd. for
C28H31N2O4Cl3 m.w. 565.84: %C 59.42; %H 5.52;
%N 4.95. Found: %C 59.32; %H 5.62; %N 4.89; IR
(KBr, cm-1): 2988, 2954, 1657, 1619, 1592, 1274,
1245, 1226, 1120; 1H NMR (base) 300 MHz (δH
ppm): 2.28 (s, 3H, CH3-Ar), 3.2-4.0 (m, 12H, CH2-
N), 4.4 (brs, 2H, CH2-O), 4.55 (brs, 2H, CH2-O),
6.85-8.18 (m, 10H, H-arom. (phenyl, xanthone)). 
2-((4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-
yl)methyl)-9H-xanthen-9-one dihydrochloride (II)
M.p. 278-280OC; (m.p. base 117-119OC);
Analysis: calcd. for C27H30N2O4Cl2 ◊ 1/2 H2O m.w.
526,52: %C 61.58; %H 5.93; %N 5.32. Found: %C
61.27; %H 5.76; %N 5.34; IR (base) (KBr, cm-1):
2933, 2804, 1661, 1619, 1609, 1263, 1252, 1233,
1120; 1H NMR (base) 500.13 MHz (δH ppm): 2.36-
2.58 (m, 8H, CH2 (pip.)), 2.66 (t, J = 6.0 Hz, 2H,
CH2-N), 3.59 (s, 2H, Ar-CH2-N), 3.69 (s, 3H, O-
CH3), 3.98 (t, J = 6.0 Hz, 2H, CH2-O-Ar), 6.82-6.87
(m, 4H, H-arom. (phenyl)), 7.48 (ddd, J = 0.5 Hz, J
= 1.0 Hz, J = 7.1 Hz, 1H, H-7), 7.62 (d, J = 8.7 Hz,
1H, H-4), 7.66 (ddd, J = 0.5 Hz, J = 1.0 Hz, J = 8.4
Hz, 1H, H-5), 7.79 (dd, J = 2.2 Hz, J = 8.7 Hz, 1H,
H-3), 7.88 (ddd, J = 1.71 Hz, J = 7.1 Hz, J = 8.4 Hz,
1H, H-6), 8.10 (d, J = 2.2 Hz, 1H, H-1), 8.20 (dd, J
= 1.7 Hz, J = 7.9 Hz, 1H, H-8); RF = 0.17
(toluene/acetone (5:3, v/v)).
2-((4-(2-(4-Chlor-3-methylphenoxy)ethyl)piper-
azin-1-yl)methyl)-9H-xanthen-9-one dihydrochlo-
ride (III)
M.p. 291-293oC; (m.p. base 116-118oC);
Analysis: calcd. for C27H29N2O3Cl3 m.w. 534.88:
%C 60.52; %H 5.45; %N 5.22. Found: %C 60.81;
%H 5.20; %N 5.32; IR (base) (KBr, cm-1): 3035,
2947, 2811,1651, 1620, 1592, 1464, 1230, 1134; 1H
NMR (base) 500.13 MHz (δH ppm): 2.27 (s, 3H,
CH3), 2.37-2.55 (m, 4H, CH2 (pip.(e))), 2.68 (t, J =
5.9 Hz, 2H, CH2-N), 3.38-3.45 (m, 4H, CH2
(pip.(a))), 3.60 (s, 2H, Ar-CH2-N), 4.04 (t, J = 5.9
Hz, 3H, O-CH3), 6.78 (dd, J = 3.0 Hz, J = 8.8 Hz,
1H, H-6 (phenyl)), 6.94 (d, J = 3.0 Hz, 1H, H-2
(phenyl)), 7.26 (d, J = 8.8 Hz, 1H, H-5 (phenyl)),
7.49 (ddd, J = 1.0 Hz, J = 7.1 Hz, J = 8.0 Hz, 1H, H-
7), 7.64 (d, J = 8.5 Hz, 1H, H-5), 7.67 (dd, J = 0.7
Hz, J = 8.4 Hz, 1H, H-4), 7.80 (dd, J = 2.2 Hz, J =
8.6 Hz, 1H, H-6), 7.88 (ddd, J = 1.7 Hz, J = 7.1 Hz,
J = 8.6 Hz, 1H, H-8), 8.09 (d, J = 2.0 Hz, 1H, H-3),
8.20 (dd, J = 1.6 Hz, J = 7.9 Hz, 1H, H-1); RF = 0.31
(toluene/acetone (5:3, v/v)).
2-((4-(2-(2,3,5-Trimethylphenoxy)ethyl)piperazin-
1-yl)methyl)-9H-xanthen-9-one (IV)
M.p. 134-136oC; Analysis: calcd. for
C29H37N2O3 m.w. 456.56: %C 76.28; %H 7.06; %N
6.13. Found: %C 75.88; %H 7.03; %N 6.33; IR
(KBr, cm-1): 2930, 2809, 1665, 1611, 1586, 1491,
1323, 1246, 1216, 1113; 1H NMR 500.13 MHz (δH
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ppm): 2.01 (s, 3H, CH3-Ar), 2.14 (s, 3H, CH3-Ar),
2.20 (s, 3H, CH3-Ar), 2.41-2.46 (m, 4H, CH2
(pip.(e))), 2.51-2.57 (m, 4H, CH2 (pip.(a))), 2.71 (t,
J = 5.9 Hz, 2H, CH2-N), 3.60 (s, 2H, Ar-CH2-N),
4.01 (t, J = 5.9 Hz, 2H, CH2-O), 6.55 (brs, 1H, H-4
(phenyl)), 6.59 (brs, 1H, H-6 (phenyl)), 7.47 (ddd, J
= 1.0 Hz, J = 7.1 Hz, J = 8.0 Hz, 1H, H-7), 7.61 (dd,
J = 0.5 Hz, J = 8.5 Hz, 1H, H-4), 7.64 (ddd, J = 0.5
Hz, J = 1.0 Hz, J = 8.4 Hz, 1H, H-5), 7.79 (dd, J =
2.2 Hz, J = 8.5, 1H, H-3), 7.86 (ddd, J = 1.7 Hz, J =
7.1 Hz, J = 8.4 Hz, 1H, H-6), 8.09 (dd, J = 0.5 Hz, J
= 2.2 Hz, 1H, H-1), 8.20 (ddd, J = 0.5 Hz, J = 1.7
Hz, J = 7.9 Hz, 1H, H-8); RF = 0.35 (toluene).
Ethyl 4-((9-oxo-9H-xanthen-2-yl)methyl)piper-
azine-1-carboxylate (V)
M.p. 107-109OC; Analysis: calcd. for
C21H22N2O4 m.w. 366.39: %C 68.83; %H 6.05; %N
7.65. Found: %C 68.24; %H 5.72; %N 7.25; IR
(KBr, cm-1): 2981, 2955, 1693, 1655, 1619, 1609,
1466, 1248, 1130; 1H NMR 500.13 MHz (δH ppm):
1.19 (t, J = 7.0 Hz, 3H, CH3), 2.32-2.43 (m, 4H, CH2
(pip. (e))), 3.32-3.45 (m, 4H, CH2 (pip.(a))), 3.62 (s,
2H, Ar-CH2-N), 4.04 (q, J = 7.0 Hz, 2H, O-CH2),
7.48 (ddd, J = 1.0 Hz, J = 7.1 Hz, J = 8.0 Hz, 1H, H-
arom), 7.60 (d, J = 8.5 Hz, 1H, H-arom), 7.64 (dd, J
= 0.6 Hz, J = 8.6 Hz, 1H, H-arom.), 7.79 (dd, J = 0.6
Hz, J = 8.6 Hz, 1H, H-arom), 7.87 (ddd, J = 1.7 Hz,
J = 7.1 Hz, J = 8.6 Hz, 1H, H-arom), 8.08 (d, J = 1.9
Hz, 1H, H-arom), 8.19 (dd, J = 1.7 Hz, J = 7.9 Hz,
1H, H-arom); RF = 0.54 (toluene/acetone (5:3, v/v)).
Ethyl 4-((6-methoxy-9-oxo-9H-xanthen-2-yl)meth-
yl)piperazine-1-carboxylate (VI)
M.p. 166-168OC; Analysis: calcd. for
C22H24N2O5 m.w. 396.44: %C 66.65; %H 6.10; %N
7.07. Found: %C 66.60; %H 5.97; %N 6.88; IR
(KBr, cm-1): 2774, 1688, 1645, 1618, 1588, 1432,
1242, 1120; 1H NMR 500.13 MHz (δH ppm): 1.17 (t,
J = 7.0 Hz, 3H, CH3), 2.34-2.42 (m, 4H, CH2 (pip.
(e))), 3.35.-3.42 (m, 4H, CH2 (pip. (a))), 3.63 (s, 2H,
CH2-Ar), 3.94 (s, 3H, O-CH3), 4.03 (q, J = 7.0 Hz,
2H, CH2), 7.06 (dd, J = 2.4 Hz, J = 8.7 Hz, 1H, H-
7), 7.16 (d, J = 2.4 Hz, 1H, H-5), 7.60 (d, J = 8.6 Hz,
1H, H-4), 7.78 (dd, J = 2.2 Hz, J = 8.6 Hz, 1H, H-
3), 8.08 (d, J = 2.2 Hz, 1H, H-1), 8.11 (d, J = 8.7 Hz,
1H, H-8), RF = 0.57 (toluene/acetone (5:3, v/v)).
Ethyl 4-(9-oxo-9H-xanthene-2-carbonyl)piperazine-
1-carboxylate (VII)
M.p. 143-145OC; Analysis: calcd. for
C21H20N2O5 m.w. 380.37: %C 66.30; %H 5.30; %N
7.36. Found: %C 65.52; %H 4.80; %N 7.65; IR (KBr,
cm-1): 2970, 1700, 1666, 1624, 1458, 1289,
1264,1130; 1H NMR 500.13 MHz (δH ppm): 1.20 (t, J
= 7.2 Hz, 3H, CH3), 3.30-3.90 (m, 8H, CH2 (pip.)),
4.07 (q, J = 7.2 Hz, 2H, O-CH2), 7.52 (ddd, J = 1.8 Hz,
J = 7.1 Hz, J = 8.5 Hz, 1H, H-7), 7.70 (ddd, J = 0.5
Hz, J = 1.0 Hz, J = 8.5 Hz, 1H, H-5), 7.75 (dd, J = 2.2
Hz, J = 8.6 Hz, 1H, H-4), 7.91 (dd, J = 0.5 Hz, J = 8.6
Hz, 1H, H-6), 7.93 (ddd, J = 1.0 Hz, J = 7.1 Hz, J =
7.9 Hz, 1H, H-8), 8.21 (dd, J = 0.5 Hz, J = 2.2 Hz, 1H,
H-3), 8.21 (ddd, J = 0.5 Hz, J = 1.7 Hz, J = 7.9 Hz,
1H, H-1); RF = 0.41 (toluene/acetone (5:3, v/v)).
Ethyl 4-(6-chloro-9-oxo-9H-xanthene-2-carbonyl)
piperazine-1-carboxylate (VIII)
M.p. 197-199oC; Analysis: calcd. for
C21H19N2O5Cl m.w. 414.84: %C 60.80; %H 4.62;
%N 6.75. Found: %C 61.06; %H 4.65; %N 6.82; IR
(KBr, cm-1): 2980, 1689, 1666, 1627, 1613, 1439,
1244; 1H NMR 500.13 MHz (δH ppm): 1.17 (t, J =
7.1 Hz, 1H, CH3), 2.34-2.42 (m, 4H, CH2 (pip.(e))),
3.33-3.42 (m, 4H, CH2 (pip.(a))), 3.63 (s, 2H, CH2-
Ar), 4.03 (q, J = 7.1 Hz, 2H, CH2), 7.51 (dd, J = 2.0
Hz, J = 8.4 Hz, 1H, H-7), 7.61 (d, J = 8.6 Hz, 1H,
H-4), 7.81 (d, J = 2.0 Hz, 1H, H-5), 7.81 (dd, J = 2.2
Hz, J = 8.6 Hz, 1H, H-3), 8.07 (d, J = 2.2 Hz, 1h, H-
1), 8.17 (d, J = 8.4 Hz, 1H, H-8); RF = 0.6
(toluene/acetone (5:3, v/v)).
The physicochemical properties of compounds
IX-XX were formerly reported (24). 
Biological tests 
In vitro evaluation of antimycobacterial activity
against M. tuberculosis H37Rv.
Primary screening was conducted at doses 12.5
or 6.25 µg/mL against M. tuberculosis H37Rv (ATCC
27294; American Type Culture Collection, Rockville,
MD) in BACTEC 12B medium. Compounds exhibit-
ing fluorescence were tested in the BACTEC 460-
radiometric system (29). Compounds demonstrating
at least 90% inhibition were tested against M. tubercu-
losis H37Rv at lower concentration to determine the
actual minimum inhibitory concentration (MIC) in the
Microplate Alamar Blue Assay (MABA). The MIC
was defined as the lowest concentration effecting a
reduction in fluorescence of 90% relative to controls.
Rifampin (Sigma Chemical Company, St. Louis, MO)
was included as a positive drug control. Two com-
pounds effecting > 90% inhibition in the primary
screening were additionally tested against M. avium
(ATCC 25291) in the MABA. Clarithromycin was
included as a positive drug control. 
Cytotoxic activity 
Compounds were tested for overt cytotoxicity
(IC50) in VERO cells. After 72 h exposure, viability
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was assayed on the basis of cellular conversion of
MTT into a formazan product using the Promega
CellTiter 96 Non-radioactive Cell Proliferation
Assay. IC50 value divided by MIC equals SI coeffi-
cient, which describes cytotoxicity of compounds.
RESULTS AND DISCUSSION
Some 2-substituted xanthones were assayed for
their inhibition of M. tuberculosis activity.
Additionally, compounds expressing the highest activ-
ity were also examined both for their M. avium activ-
ity as well as their cytotoxity was evaluated. The
results of the in vitro evaluation of antituberculosis
activity are reported in Table 1. The highest level of
activity against M. tuberculosis was observed for com-
pounds III and XVIII, 98% and 94%, respectively
(21). Thus, both compounds were also examined for
their anti M. avium activity as well as their cytotoxic-
ity. Both of them revealed cytotoxic activity (SI < 1),
whereas only compound III showed significant anti
M. avium activity (88% inhibition, MIC > 12,5
µg/mL). Taking these facts into account another group
of derivatives was synthesized. Some of the presented
structures are new (I, II, IV, XV and XIX). Among the
new group of compounds I revealed the same anti M.
tuberculosis activity as its parent compound III (98%).
In addition, it was also observed that the other ana-
logues of III (II and IV) showed lower antimycobac-
terial activity. It was also noticed that within the group
of 2-piperazinylmethylxanthone derivatives a lack of
the phenoxy moiety resulted in the loss of activity
against M. tuberculosis. The same was observed for 2-
piperazinocarbonylxanthone. In the group of the 2-(3-
N-piperazino-2-hydroxy-1-propoxy)-xanthone the
presence of phenoxy moiety was not necessary for
antituberculous activity. In this group the highest
activity was observed for compound XVIII which
possesses the ethoxycarbonyl group. Hydrolysis of
this structure resulted in significant decrease in activi-
ty (3% for compound XV). In the morpholine deriva-
tives, their activity was between 9% [IX] and 63%
[XIV]). It can be stated that the longer was the chain,
the higher activity was observed.
Because the cells of mycobacteria are
hydrophobic and possess very high lipid content of
the cell envelope, constituting up to 40% of their dry
weight (30), it was of interest to compare Log Pcomb
values calculated for the bases of the examined com-
pounds (computer programs perform calculations
only for bases). In our own experience in experi-
mental determining of lipophilic parameters,
lipophilicity of hydrochlorides and appropriate
bases does not vary considerably. The calculated
values of Log Pcomb varied significantly from 1.37
for compound XVII to 4.82 for compound IV. The
comparison of the lipophilic properties indicates that
values of log P for the structures containing phenyl
moiety are higher than values of log P for the other
derivatives, what seems to be correlated with micro-
biological effects. However, no exact relation
between log P and antimycobacterial activity of the
tested compounds was found. It was observed that
two out of three compounds exhibiting the highest
activity against M. tuberculosis (I and III) possess
high log P values (more than 4.4), which was not,
however, seen for compound XVIII (log P = 2.21). 
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